Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 35

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Zhenoluten® RESEARCH METHODS The patients’ complaints were assessed in progression, a general clinical examination of blood and urine, a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany) were carried out. Ultrasound examination of the ovaries was performed using an ultrasound machine (ALOKA, Japan). The content of hormones (FSH, LH, and estradiol) in the blood serum was determined by radioimmunoassay. The radioactivity of the samples was counted on a «Tracor Analytic 1285» counter (USA-Holland). RESEARCH RESULTS It was found that the use of ZHENOLUTEN® in patients with mild and moderate climacteric syndrome contributed to an improvement in the general condition, which was manifested in a decrease in the number of hot flashes, improved sleep, appetite, and increased efficiency (Table 1). Dynamics of subjective indicators in patients with climacteric Table 1 syndrome. Indicator Number of Patients. % Before Treatment After Treatment with Conventional After Treatment with Methods (Control Group) ZHENOLUTEN® (Primary Group) Hot flushes in the head and 72,0 55,1* 31,8*# upper body. Increased sweating. 67,8 50,7* 29,6*# Fast fatiguability. 68,8 51,3* 31,4*# Reduced performance. 81,6 53,1* 32,6*# Irritability. 91,8 54,2* 33,3*# *p <0.05 compared with the indicator in patients before treatment; # p <0.05 compared with the indicator in patients after treatment with conventional methods. In laboratory studies, after the application of ZHENOLUTEN®, a significant decrease in the content of FSH and LH was noted, which caused an increase in the LH / FSH index to the lower limits of age-re- lated physiological fluctuations (Table 2). The noted changes in the hormonal status of patients while taking ZHENOLUTEN® correlate with clinical indicators. They indicate the restoration of the adequate adaptive response of the aging or- ganism in response to an age-related decrease in ovarian function. Effect of ZHENOLUTEN®on the content of pituitary hormones in blood serum Table 2 of patients with climacteric syndrome. Indicator Norm Before Treatment After Treatment with After Treatment with Conventional Drugs (Control ZHENOLUTEN® Group) (Primary Group) FSH, (IU / ml) 1,5-45 89,3±3,5 71,6±6,3* 46,8±3,9*# LH, (IU / ml) 2-17 28,1±1,9 25,7±2,4 16,4±1,4*# * p <0.05 - statistically significant compared with the indicator before treatment. # p <0.05 - statistically significant in comparison with the indicator in patients of the control group.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.